Please check your internet connection and try again.
# Sodium Phosphate Enema
## Overview
Sodium phosphate enema is a hypertonic saline solution used as a laxative and to evacuate the bowel prior to procedures or constipation.
## Primary Indications
* Bowel preparation for diagnostic or surgical procedures.
* Treatment of occasional constipation.
## Adult Dosing
* **Bowel Preparation:** One 4.5 oz (133 mL) bottle administered rectally as a single dose. May be repeated as directed by a healthcare provider.
* **Constipation:** One 2.25 oz (66 mL) bottle administered rectally as a single dose. May be repeated as directed by a healthcare provider, but not more than one dose in 24 hours.
## Pediatric Dosing
* **Children 2-12 years:** 2.25 oz (66 mL) bottle administered rectally as a single dose.
* **Children under 2 years:** Use is generally not recommended due to risk of significant electrolyte imbalance. Consult a pediatrician.
## Dose Adjustments
* No specific dose adjustments are typically required for renal or hepatic impairment, but caution is advised due to the potential for electrolyte disturbances.
## Contraindications
* Congestive heart failure.
* Newly diagnosed or existing kidney disease.
* Congenital megacolon.
* Gastrointestinal obstruction.
* Abdominal pain of unknown origin.
* Children under 2 years of age.
* Patients who are unable to retain the enema.
* Hypersensitivity to sodium phosphate.
## Adverse Effects
* **Common:** Abdominal cramping, nausea, vomiting, bloating, rectal irritation.
* **Serious:** Hyperphosphatemia, hypocalcemia, hypernatremia, hypokalemia, dehydration, cardiac arrhythmias, seizures, renal damage, and potentially fatal electrolyte imbalances, especially with overuse or in susceptible individuals.
## Key Drug Interactions
* Diuretics, ACE inhibitors, ARBs, NSAIDs: Increased risk of hyperphosphatemia and renal toxicity.
* Calcium-containing medications: May increase the risk of hyperphosphatemia and renal calcification.
* Magnesium-containing medications: May potentiate electrolyte imbalances.
## Monitoring
* Monitor for signs and symptoms of dehydration and electrolyte imbalance (e.g., thirst, decreased urination, fatigue, muscle cramps, confusion, dizziness).
* Consider baseline and follow-up electrolytes and renal function in patients with risk factors.
## Clinical Pearls
* Ensure adequate hydration before and after administration.
* Administer slowly and retain for the recommended time (usually 5-15 minutes) to ensure efficacy and minimize cramping.
* Avoid use in elderly, debilitated, or very young patients, and those with compromised renal function, due to increased risk of electrolyte abnormalities.
* Limit frequency to avoid dependence and electrolyte disturbances.
***
*Please verify the current prescribing information with official drug resources before initiating or modifying therapy.*
